» Articles » PMID: 34200905

Cell-Based Therapies for Traumatic Brain Injury: Therapeutic Treatments and Clinical Trials

Overview
Journal Biomedicines
Date 2021 Jul 2
PMID 34200905
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Traumatic brain injury (TBI) represents physical damage to the brain tissue that induces transitory or permanent neurological disabilities. TBI contributes to 50% of all trauma deaths, with many enduring long-term consequences and significant medical and rehabilitation costs. There is currently no therapy to reverse the effects associated with TBI. An increasing amount of research has been undertaken regarding the use of different stem cells (SCs) to treat the consequences of brain damage. Neural stem cells (NSCs) (adult and embryonic) and mesenchymal stromal cells (MSCs) have shown efficacy in pre-clinical models of TBI and in their introduction to clinical research. The purpose of this review is to provide an overview of TBI and the state of clinical trials aimed at evaluating the use of stem cell-based therapies in TBI. The primary aim of these studies is to investigate the safety and efficacy of the use of SCs to treat this disease. Although an increasing number of studies are being carried out, few results are currently available. In addition, we present our research regarding the use of cell therapy in TBI. There is still a significant lack of understanding regarding the cell therapy mechanisms for the treatment of TBI. Thus, future studies are needed to evaluate the feasibility of the transplantation of SCs in TBI.

Citing Articles

Mesenchymal stromal cell therapies for traumatic neurological injuries.

Wang X, Wang Q, Xia Z, Yang Y, Dai X, Zhang C J Transl Med. 2024; 22(1):1055.

PMID: 39578845 PMC: 11583761. DOI: 10.1186/s12967-024-05725-3.


Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.

Krsek A, Jagodic A, Baticic L Medicina (Kaunas). 2024; 60(9).

PMID: 39336425 PMC: 11433843. DOI: 10.3390/medicina60091384.


The Current Update of Conventional and Innovative Treatment Strategies for Central Nervous System Injury.

Tsai M, Wu C, Wu C, Chen C Biomedicines. 2024; 12(8).

PMID: 39200357 PMC: 11351448. DOI: 10.3390/biomedicines12081894.


Mapping knowledge of the stem cell in traumatic brain injury: a bibliometric and visualized analysis.

Deng T, Ding R, Wang Y, Chen Y, Sun H, Zheng M Front Neurol. 2024; 15:1301277.

PMID: 38523616 PMC: 10957745. DOI: 10.3389/fneur.2024.1301277.


Neuroinflammation and acquired traumatic CNS injury: a mini review.

Theus M Front Neurol. 2024; 15:1334847.

PMID: 38450073 PMC: 10915049. DOI: 10.3389/fneur.2024.1334847.


References
1.
Wu D, Boyd A, Wood K . Embryonic stem cell transplantation: potential applicability in cell replacement therapy and regenerative medicine. Front Biosci. 2007; 12:4525-35. DOI: 10.2741/2407. View

2.
Sanchez-Ramos J, Song S, Cardozo-Pelaez F, HAZZI C, Stedeford T, Willing A . Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol. 2000; 164(2):247-56. DOI: 10.1006/exnr.2000.7389. View

3.
Riess P, Zhang C, Saatman K, Laurer H, Longhi L, Raghupathi R . Transplanted neural stem cells survive, differentiate, and improve neurological motor function after experimental traumatic brain injury. Neurosurgery. 2002; 51(4):1043-52; discussion 1052-4. DOI: 10.1097/00006123-200210000-00035. View

4.
Hong S, Zhang H, You J, Zhang M, Cai Y, Jiang X . Comparison of transdifferentiated and untransdifferentiated human umbilical mesenchymal stem cells in rats after traumatic brain injury. Neurochem Res. 2011; 36(12):2391-400. DOI: 10.1007/s11064-011-0567-2. View

5.
Fong C, Chak L, Biswas A, Tan J, Gauthaman K, Chan W . Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev Rep. 2010; 7(1):1-16. DOI: 10.1007/s12015-010-9166-x. View